aspirin has been researched along with Microsatellite Instability in 9 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Microsatellite Instability: The occurrence of highly polymorphic mono- and dinucleotide MICROSATELLITE REPEATS in somatic cells. It is a form of genome instability associated with defects in DNA MISMATCH REPAIR.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Regular use of aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) for a longer period has been inversely associated with colorectal cancer (CRC) risk." | 7.91 | Association of Aspirin and Nonsteroidal Anti-Inflammatory Drugs With Colorectal Cancer Risk by Molecular Subtypes. ( Amitay, EL; Bläker, H; Brenner, H; Carr, PR; Chang-Claude, J; Herpel, E; Hoffmeister, M; Jansen, L; Kloor, M; Roth, W; Walter, V, 2019) |
| "Purpose Regular use of aspirin is associated with improved survival for patients with colorectal cancer (CRC)." | 7.85 | Timing of Aspirin and Other Nonsteroidal Anti-Inflammatory Drug Use Among Patients With Colorectal Cancer in Relation to Tumor Markers and Survival. ( Adams, SV; Ahnen, DJ; Baron, JA; Burnett-Hartman, AN; Cohen, SA; Hardikar, S; Hua, X; Kocarnik, JM; Lindor, NM; Newcomb, PA; Phipps, AI, 2017) |
| " Aspirin and sulindac have been shown to be effective in selecting for cells with reduced microsatellite instability (MSI) that is inherent in mismatch repair (MMR)-deficient hereditary nonpolyposis colorectal cancer (HNPCC) cells." | 7.74 | Nitric oxide-donating aspirin derivatives suppress microsatellite instability in mismatch repair-deficient and hereditary nonpolyposis colorectal cancer cells. ( Burkholder, S; Fishel, R; Kopelovich, L; McIlhatton, MA; Rigas, B; Ruschoff, J; Tyler, J, 2007) |
| "Aspirin reduces the incidence of conventional adenomas driven by APC mutation and thus colorectal cancer." | 4.02 | Aspirin reduces the incidence of metastasis in a pre-clinical study of Braf mutant serrated colorectal neoplasia. ( Bond, CE; Fennell, LJ; Kane, AM; Leggett, BA; Liu, C; McKeone, DM; Pollock, PM; Whitehall, VLJ; Young, G, 2021) |
| "Regular use of aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) for a longer period has been inversely associated with colorectal cancer (CRC) risk." | 3.91 | Association of Aspirin and Nonsteroidal Anti-Inflammatory Drugs With Colorectal Cancer Risk by Molecular Subtypes. ( Amitay, EL; Bläker, H; Brenner, H; Carr, PR; Chang-Claude, J; Herpel, E; Hoffmeister, M; Jansen, L; Kloor, M; Roth, W; Walter, V, 2019) |
| "Purpose Regular use of aspirin is associated with improved survival for patients with colorectal cancer (CRC)." | 3.85 | Timing of Aspirin and Other Nonsteroidal Anti-Inflammatory Drug Use Among Patients With Colorectal Cancer in Relation to Tumor Markers and Survival. ( Adams, SV; Ahnen, DJ; Baron, JA; Burnett-Hartman, AN; Cohen, SA; Hardikar, S; Hua, X; Kocarnik, JM; Lindor, NM; Newcomb, PA; Phipps, AI, 2017) |
| " We evaluated the effects of aspirin on genetic/epigenetic alterations in precancerous conditions, i." | 3.85 | Effects of long-term aspirin use on molecular alterations in precancerous gastric mucosa in patients with and without gastric cancer. ( Das, KM; Fukui, H; Hara, K; Ito, C; Kondo, T; Kono, T; Michigami, Y; Miwa, H; Morimoto, T; Oshima, T; Tomita, T; Tozawa, K; Watari, J; Yamasaki, T, 2017) |
| " Previous cellular studies showed that aspirin (acetylsalicylic acid: ASA) and nitric oxide-donating ASA (NO-ASA) suppressed microsatellite instability (MSI) in mismatch repair (MMR)-deficient cells linked to the common cancer predisposition syndrome hereditary nonpolyposis colorectal cancer or Lynch syndrome (LS/HNPCC), at doses 300- to 3,000-fold less than ASA." | 3.77 | Aspirin and low-dose nitric oxide-donating aspirin increase life span in a Lynch syndrome mouse model. ( Bocker-Edmonston, T; Edelmann, W; Fishel, R; Kerepesi, LA; Kopelovich, L; Kucherlapati, MH; Kucherlapati, R; McIlhatton, MA; Tyler, J, 2011) |
| " Aspirin and sulindac have been shown to be effective in selecting for cells with reduced microsatellite instability (MSI) that is inherent in mismatch repair (MMR)-deficient hereditary nonpolyposis colorectal cancer (HNPCC) cells." | 3.74 | Nitric oxide-donating aspirin derivatives suppress microsatellite instability in mismatch repair-deficient and hereditary nonpolyposis colorectal cancer cells. ( Burkholder, S; Fishel, R; Kopelovich, L; McIlhatton, MA; Rigas, B; Ruschoff, J; Tyler, J, 2007) |
| "Lynch syndrome is an autosomal-dominant hereditary cancer syndrome." | 2.55 | Approach to Lynch Syndrome for the Gastroenterologist. ( Bui, QM; Ho, W; Lin, D, 2017) |
| "Using data from a large study of colon cancer, we examine genetic variants in insulin, inflammation, estrogen, metabolizing enzymes, and energy homeostasis genes to explore associations with microsatellite instability (MSI), CpG Island methylator phenotype (CIMP), mutations of p53 in exons 5 through 8, and mutations in codons 12 and 13 of Ki-ras." | 1.35 | Colon tumor mutations and epigenetic changes associated with genetic polymorphism: insight into disease pathways. ( Caan, BJ; Curtin, K; Fitzpatrick, F; Herrick, J; Potter, JD; Samowitz, WS; Slattery, ML; Wolff, RK, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Kane, AM | 1 |
| Liu, C | 1 |
| Fennell, LJ | 1 |
| McKeone, DM | 1 |
| Bond, CE | 1 |
| Pollock, PM | 1 |
| Young, G | 1 |
| Leggett, BA | 1 |
| Whitehall, VLJ | 1 |
| Hua, X | 1 |
| Phipps, AI | 1 |
| Burnett-Hartman, AN | 1 |
| Adams, SV | 1 |
| Hardikar, S | 1 |
| Cohen, SA | 1 |
| Kocarnik, JM | 1 |
| Ahnen, DJ | 1 |
| Lindor, NM | 1 |
| Baron, JA | 1 |
| Newcomb, PA | 1 |
| Michigami, Y | 1 |
| Watari, J | 1 |
| Ito, C | 1 |
| Hara, K | 1 |
| Yamasaki, T | 1 |
| Kondo, T | 1 |
| Kono, T | 1 |
| Tozawa, K | 1 |
| Tomita, T | 1 |
| Oshima, T | 1 |
| Fukui, H | 1 |
| Morimoto, T | 1 |
| Das, KM | 1 |
| Miwa, H | 1 |
| Amitay, EL | 1 |
| Carr, PR | 1 |
| Jansen, L | 1 |
| Walter, V | 1 |
| Roth, W | 1 |
| Herpel, E | 1 |
| Kloor, M | 1 |
| Bläker, H | 1 |
| Chang-Claude, J | 1 |
| Brenner, H | 1 |
| Hoffmeister, M | 1 |
| Bui, QM | 1 |
| Lin, D | 1 |
| Ho, W | 1 |
| Slattery, ML | 1 |
| Wolff, RK | 1 |
| Curtin, K | 1 |
| Fitzpatrick, F | 1 |
| Herrick, J | 1 |
| Potter, JD | 1 |
| Caan, BJ | 1 |
| Samowitz, WS | 1 |
| McIlhatton, MA | 2 |
| Tyler, J | 2 |
| Kerepesi, LA | 1 |
| Bocker-Edmonston, T | 1 |
| Kucherlapati, MH | 1 |
| Edelmann, W | 1 |
| Kucherlapati, R | 1 |
| Kopelovich, L | 2 |
| Fishel, R | 2 |
| Burn, J | 1 |
| Mathers, J | 1 |
| Bishop, DT | 1 |
| Burkholder, S | 1 |
| Ruschoff, J | 1 |
| Rigas, B | 1 |
1 review available for aspirin and Microsatellite Instability
| Article | Year |
|---|---|
Approach to Lynch Syndrome for the Gastroenterologist.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma; Colectomy; Colonoscopy; Colore | 2017 |
8 other studies available for aspirin and Microsatellite Instability
| Article | Year |
|---|---|
Aspirin reduces the incidence of metastasis in a pre-clinical study of Braf mutant serrated colorectal neoplasia.
Topics: Adenoma; Animals; Aspirin; Colorectal Neoplasms; Disease Models, Animal; Female; Incidence; Male; Mi | 2021 |
Timing of Aspirin and Other Nonsteroidal Anti-Inflammatory Drug Use Among Patients With Colorectal Cancer in Relation to Tumor Markers and Survival.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers, Tumor; Colorectal Neoplasms; Fem | 2017 |
Effects of long-term aspirin use on molecular alterations in precancerous gastric mucosa in patients with and without gastric cancer.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; CpG | 2017 |
Association of Aspirin and Nonsteroidal Anti-Inflammatory Drugs With Colorectal Cancer Risk by Molecular Subtypes.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Colorectal Neoplasms; | 2019 |
Colon tumor mutations and epigenetic changes associated with genetic polymorphism: insight into disease pathways.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arylamine N-Acetyltransferase; Aspirin; Case-C | 2009 |
Aspirin and low-dose nitric oxide-donating aspirin increase life span in a Lynch syndrome mouse model.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Base Pair Mismatch; Colorectal Neoplasms, | 2011 |
Lynch syndrome: history, causes, diagnosis, treatment and prevention (CAPP2 trial).
Topics: Anticarcinogenic Agents; Aspirin; Colorectal Neoplasms, Hereditary Nonpolyposis; DNA Mismatch Repair | 2012 |
Nitric oxide-donating aspirin derivatives suppress microsatellite instability in mismatch repair-deficient and hereditary nonpolyposis colorectal cancer cells.
Topics: Animals; Aspirin; Base Pair Mismatch; Cell Line, Tumor; Colon; Colorectal Neoplasms, Hereditary Nonp | 2007 |